Core Insights - Johnson & Johnson (JNJ) announced FDA approval for Icotyde, a once-daily oral peptide for treating plaque psoriasis, which selectively blocks the interleukin-23 receptor (IL-23) [1] Company Overview - Icotyde was developed in collaboration with Brendan, who has a strong academic and professional background in organic synthesis and biotechnology [1] Industry Context - The approval of Icotyde represents a significant advancement in the treatment options available for plaque psoriasis, highlighting ongoing innovation in the biotechnology sector [1]

Johnson & Johnson (NYSE:JNJ) ranks among the best most active stocks to buy right now. On March 13, Johnson & Johnson (NYSE:JNJ) revealed results from a Phase 1 study of an innovative intravesical drug-releasing mechanism with erdafitinib (Erda-iDRS) in patients with non-muscle-invasive bladder cancer who had specific fibroblast growth factor receptor mutations. Pixabay/Public Domain According to the company, the trial met its major safety goals. The intermediate-risk sample of 62 patients had an 89% co ...

Core Insights - TuHURA Biosciences has appointed Dr. Craig L. Tendler as the leader of its VISTA Program in AML and other blood-related cancers, while he continues his role on the Board of Directors [1][2] - Dr. Tendler brings over 29 years of experience in drug development, having coordinated over 30 oncology regulatory approvals and 15 new medical entity approvals, contributing to more than $16 billion in global sales from multiple myeloma treatments [1][2] - The company is focused on developing TBS-2025, a VISTA inhibiting antibody, which is expected to address immunosuppressive roles in AML, particularly in NPM1 mutated cases [2][6] Company Overview - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company that develops novel therapeutics aimed at overcoming resistance to cancer immunotherapy [4] - The company’s lead product, IFx-2.0, is designed to counter primary resistance to checkpoint inhibitors and is currently undergoing a Phase 3 trial in combination with Keytruda® for advanced Merkel Cell Carcinoma [5] - TuHURA acquired TBS-2025 through a merger with Kineta Inc. and is advancing it into Phase 2 development for mutNPM1 r/r AML [6] Leadership and Experience - Dr. Tendler previously served as Vice President of Oncology Clinical Development at Johnson & Johnson, where he was instrumental in securing global approvals for several oncology treatments [2][3] - His experience includes leading clinical diligence teams for significant acquisitions and co-development agreements in the oncology sector [2][3] - Dr. Tendler has also held academic positions and has been involved in various cancer research initiatives, enhancing his expertise in the field [3]

Core Viewpoint - Johnson & Johnson received FDA approval for ICOTYDE, an oral treatment for moderate to severe plaque psoriasis, which is seen as a positive development despite the stock's recent decline [1]. Group 1: Company Overview - Johnson & Johnson develops and sells healthcare products, including pharmaceuticals and medical technologies, with a focus on immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2]. Group 2: Market Reaction - Despite the positive news regarding FDA approval, the stock finished down 0.35% in a challenging market session, indicating that broader market conditions may have overshadowed the company's announcement [1]. - The current market environment is described as a "terrible, horrible, no good, very bad day," suggesting that such conditions may create buying opportunities for investors in Johnson & Johnson [1].

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers six different portfolios tailored for various income-seeking investors, including retirees or near-retirees [1] - The portfolios include two High-Income portfolios, a Dividend Growth Investing (DGI) portfolio, a conservative strategy for 401K accounts, a Sector-Rotation strategy, and a High-Growth portfolio [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for lower drawdowns and sustainable yields [2] - The service is designed to help investors create stable, long-term passive income [2]

Core Insights - Protagonist Therapeutics (PTGX) shares have increased nearly 7% following the FDA approval of icotrokinra, developed in partnership with Johnson & Johnson (JNJ), for treating moderate-to-severe plaque psoriasis in patients aged 12 and older [1][6] FDA Approval and Product Details - Icotrokinra, marketed as Icotyde in the U.S., is the first targeted oral peptide designed to inhibit the IL-23 receptor [2][4] - The FDA approval was supported by data from four phase III studies within the ICONIC program, demonstrating significant skin clearance and a favorable safety profile [4] Financial Implications - Protagonist will receive a $50 million milestone payment from JNJ, with potential for up to $580 million more in regulatory and sales-based milestones [6][7] - Protagonist is entitled to tiered royalties on global net sales, ranging from 6% to 10%, with an average of approximately 7.25% at $4 billion in annual sales [7] Market Potential - JNJ believes Icotyde has the potential to revolutionize plaque psoriasis treatment as a once-daily oral alternative to existing injectables [8] - Icotyde is also being evaluated for other indications, including psoriatic arthritis and inflammatory bowel diseases, indicating broader market potential [9]

FDA Approvals & Rejections - GSK's Lynavoy received FDA approval as the first treatment for cholestatic pruritus in adults with primary biliary cholangitis, supported by Phase 3 GLISTEN trial data showing significant reductions in itching and sleep disturbance compared to placebo [2] - Knight Therapeutics gained approval in Brazil for MINJUVI in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, backed by clinical data demonstrating meaningful response rates [4][5] - Novartis' Cosentyx was approved for treating moderate to severe hidradenitis suppurativa in adolescents aged 12 and older, making it the first IL-17A inhibitor approved for this age group [6][7] - Myriad Genetics' MyChoice CDx test was approved as a companion diagnostic for GSK's Zejula in advanced ovarian cancer, being the only FDA-approved HRD test for this purpose [9][10] - Aldeyra Therapeutics faced another FDA rejection for Reproxalap in dry eye disease, with shares plummeting nearly 75% following the Complete Response Letter citing lack of substantial evidence [11][12][13] - Telix Pharmaceuticals resubmitted its NDA for TLX101-Px, an investigational PET imaging agent for glioma, addressing previous FDA concerns [14][15] - Rhythm Pharmaceuticals received FDA approval for IMCIVREE to treat acquired hypothalamic obesity, supported by Phase 3 TRANSCEND trial results showing a significant BMI reduction [16] - Novo Nordisk's Wegovy HD was approved for weight loss, showing an average weight loss of 20.7% in the STEP UP trial, with a launch expected in April 2026 [17][18] Clinical Trials - Breakthroughs & Setbacks - Ascendis Pharma reported positive results from its Phase 2 trial for TransCon hGH in Turner syndrome, showing similar annualized height velocity compared to daily somatropin [24][25] - CytomX Therapeutics announced positive expansion data for Varseta-M in late-line metastatic colorectal cancer, with a disease control rate of 88% across evaluated doses [26][28][29] - Rhythm Pharmaceuticals' EMANATE trial missed its primary endpoint but showed significant BMI reductions in specific genetic subgroups, with no new safety concerns reported [30][32] - Sana Biotechnology reported positive 14-month results from a study on UP421 for type 1 diabetes, demonstrating sustained function of pancreatic beta cells and successful immune evasion [33][34][35] - Immutep discontinued its Phase III trial of Eftilagimod Alfa in first-line non-small cell lung cancer due to futility as recommended by the Independent Data Monitoring Committee [36][37]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8]

Core Insights - Johnson & Johnson (JNJ) has made significant advancements in its pipeline, achieving key clinical and regulatory milestones that are expected to drive growth through the latter half of the decade [1] - The company received approvals for new products, including Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis [1] Product Approvals and Pipeline - Inlexzoh is a novel drug-releasing system that allows for sustained local delivery of cancer treatment directly into the bladder [2] - Nipocalimab, an FcRn blocker, is under review for multiple immune-mediated conditions, including warm autoimmune hemolytic anemia and systemic lupus erythematosus, with potential for significant market impact [2] - In 2026, J&J and Protagonist Therapeutics received FDA approval for icotrokinra (marketed as Icotyde), an oral targeted peptide inhibitor for moderate-to-severe plaque psoriasis [3][10] - Icotyde's approval was based on data from four phase III studies, demonstrating significant skin clearance and a favorable safety profile [4] - Icotyde is expected to revolutionize plaque psoriasis treatment by offering a once-daily oral option, contrasting with existing injectable treatments [5][6] Market Potential - J&J anticipates that Inlexzoh, Icotyde, and Imaavy are among ten new drugs that could collectively achieve peak sales of $5 billion [7] - The company expects a more pronounced impact from new products in 2026 compared to 2025, highlighting the strength of its late-stage pipeline [8] Financial Performance - JNJ's shares have outperformed the industry, rising 45.6% over the past year compared to an 8.0% increase in the industry [9] - The company's shares currently trade at a price/earnings ratio of 20.23, higher than the industry average of 17.25, indicating a slightly expensive valuation [11] - The Zacks Consensus Estimate for 2026 earnings has increased from $11.46 to $11.54, while the estimate for 2027 has risen from $12.25 to $12.44 [12]

Group 1 - Johnson & Johnson (NYSE: JNJ) is highlighted as a stock that should have increased in value, with a focus on buying rather than selling during market downturns [1] - The stock market is currently viewed as oversold, indicated by a -7 reading on the S&P Oscillator, suggesting excessive selling pressure [1] - Johnson & Johnson develops and sells a range of healthcare products, including pharmaceuticals and medical technologies, with a focus on various therapeutic areas such as immunology and oncology [2] Group 2 - While Johnson & Johnson is recognized for its investment potential, certain AI stocks are considered to offer greater upside potential and lower downside risk [3]